Company Profile

QSM Diagnostics Inc (AKA: QSM)
Profile last edited on: 10/20/20      CAGE: 7BP67      UEI: KMSCCK74WGK5

Business Identifier: Sensors for point-of-care infection detection and monitoring
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

38 Wareham Street Third Floor
Boston, MA 02118
   (617) 756-4024
Location: Single
Congr. District: 07
County: Suffolk

Public Profile

Spun out of the Goluch Group at Northeastern University, Boston, MA., QSM Diagnostics, the principals of the firm bring several decades of experience in the development and commercialization of medical devices with particular expertise in sensor development. The firm is organized around developing a point-of-care diagnostics for identification of bacterial infections with the firm's initial product being designed for assisting in the determination of urinary tract infection in human and animal samples. Tests for other infectious diseases are in development. Multiple patents pending in the areas of electrochemical sensing will allow development of the means to detect target molecules faster, more reliably, using a one-step method. The firm's tests can be performed directly in any biological fluid with zero sample preparation or incubation. The systems electrochemical output allows use of a battery powered handheld reader to obtain the test results in minutes. The capability also exists to detect and quantify multiple biomarkers simultaneously in a single test. With the focus currently on rapid tests for medical and healthcare applications, QSM Diagnostics's first product is a dog ear infection sensor that will be available for purchase soon.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2018 1 NSF $225,000
Project Title: Point-of-Care Test for Identifying Gram-Negative Urinary Tract Infections in Companion Animals

Key People / Management

  Philip Devlin -- CEO

  Edgar D Goluch -- Founder and President

  Nicholas Cadirov -- Director of Engineering

Company News

There are no news available.